“In Korea, they have over 70 neurotoxin competitors,” Kim said. “Botox is considered a very good product there, but the problem is it’s expensive. So Letybo, or Botulax, is viewed as a great product — ...

Before Letybo was approved, there were five neuromodulators available to injectors in the US: Botox, Xeomin, Dysport, Daxxify ...

THE WHAT? South Korea-based Hugel has announced its strongest-ever annual performance in 2024, with KRW373.0 billion in net sales, KRW166.3 billion in operating profit, and KRW142.4 billion in net ...

- The company reports KRW373.0 billion in net sales, KRW166.3 billion in operating profit, and KRW142.4 billion in net income, reflecting year-over-year increases of 16.7%, 41.2%, and 45.8%, ...

- The company reports KRW373.0 billion in net sales, KRW166.3 billion in operating profit, and KRW142.4 billion in net income, reflecting year-over-year increases of 16.7%, 41.2%, and 45.8% ...

Hugel's botulinum toxin, branded as Botulax in South Korea and globally known as Letybo, achieved KRW203.2 billion in net sales in 2024 with a 20.2% increase on-year.